Hong Kong-listed Sino Biopharmaceutical said on Tuesday that it will acquire China-based Hangzhou Hygieia Biomedical for up to 1.20 billion yuan ($172.04 million) as part of efforts to strengthen its portfolio of treatments for chronic diseases.
13 Jan 2026-14:42
13 Jan 2026-14:42
